Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

45.43
+2.335.41%
Post-market: 45.750.3200+0.70%19:05 EDT
Volume:3.73M
Turnover:170.00M
Market Cap:5.38B
PE:-8.63
High:47.00
Open:42.72
Low:42.70
Close:43.10
Loading ...

Cytokinetics announces launch of EARTH-HCM

TIPRANKS
·
20 Mar

Cytokinetics Announces Launch of Earth-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

THOMSON REUTERS
·
20 Mar

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

GlobeNewswire
·
20 Mar

Top Executive Cashes In on Cytokinetics Stock!

TIPRANKS
·
19 Mar

BRIEF-Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4)

Reuters
·
19 Mar

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
19 Mar

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
19 Mar

Promising Potential of Cytokinetics’ Aficamten in Cardiac Treatment Drives Buy Recommendation

TIPRANKS
·
18 Mar

Cytokinetics’ data supports aficamten’s potential, says H.C. Wainwright

TIPRANKS
·
18 Mar

UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating

MT Newswires Live
·
17 Mar

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

GlobeNewswire
·
17 Mar

Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment

TIPRANKS
·
10 Mar

Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley

TIPRANKS
·
10 Mar

RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view

TIPRANKS
·
10 Mar

BRIEF-Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA

Reuters
·
10 Mar

Cytokinetics: Maintain Expectation for Differentiated Label & Risk Mitigation Profile for Aficamten, IF Approved by FDA

THOMSON REUTERS
·
10 Mar